Pds biotechnology corp (EDGE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Operating expenses:
Research and development expenses

1,971

1,348

1,834

1,886

1,030

266

194

168

201

10,833

6,913

8,975

7,589

6,778

6,724

5,975

5,346

5,265

6,507

3,195

2,871

2,418

General and administrative expenses

2,060

1,623

3,068

2,383

3,905

1,337

516

398

535

5,289

3,990

4,173

4,201

4,159

3,552

3,288

3,685

3,605

1,976

1,765

1,311

1,141

Lease termination costs

-

-

-944

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring expenses

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

Impairment of machinery and equipment

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

Total operating expenses

4,031

5,980

5,847

4,270

4,935

1,631

710

567

736

16,123

10,903

13,148

11,791

10,938

10,276

9,264

9,032

8,871

8,484

4,960

4,182

3,560

Loss from operations

-4,031

-5,980

-5,847

-4,270

-4,935

-1,631

-710

-567

-736

-16,123

-10,903

-13,148

-11,791

-10,938

-10,276

-9,264

-9,032

-8,871

-8,484

-4,960

-4,182

-3,560

Other income (expense):
Bargain purchase gain

0

1,395

0

209

11,729

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

46

58

95

175

23

-0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

221

214

168

96

64

56

49

42

6

1

1

0

0

Interest expense

0

32

0

0

0

0

0

0

0

588

592

524

475

486

375

161

180

201

213

211

190

47

Warrant remeasurement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,433

350

96

-89

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

163

-

-

-

0

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,518

Income taxes (benefit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net income (loss)

-3,985

-4,177

-5,751

-3,885

6,816

-1,819

-711

-567

-737

-13,903

-11,281

-13,504

-12,170

-9,515

-10,759

-9,376

-9,170

-7,959

-10,130

-5,520

-4,468

-3,518

Comprehensive income (loss)

-3,985

-4,177

-5,751

-3,885

6,816

-1,819

-711

-567

-737

-

-11,281

-

-12,170

-9,515

-10,759

-9,376

-9,170

-7,959

-10,130

-5,520

-4,468

-

Net loss per share, basic and diluted (in dollars per share)

-

-

-1.10

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Per share information:
Net income (loss) per share, basic (in dollars per share)

-0.39

-

-

-0.75

1.82

-

-

-0.17

-0.24

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted (in dollars per share)

-0.39

-

-

-0.75

1.47

-

-

-0.17

-0.24

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing basic net (loss) income per share (in shares)

10,314

-

-

5,175

3,748

-

-

3,338

3,099

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing diluted net (loss) income per share (in shares)

10,314

-

-

5,175

4,625

-

-

3,338

3,099

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative dividend on Series C , C-1 and C-2 convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

99

1,827

1,746

683

364

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,058

-11,957

-7,267

-5,151

-3,882

Loss per share attributable to common stockholders basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-0.44

-0.37

-0.44

-0.42

-0.32

-0.37

-0.33

-0.32

10.42

-7.08

-4.30

-3.05

-2.30

Weighted average common shares outstanding basic and diluted (in shares)

-

-

5,246

-

-

-

3,346

-

-

31,321

30,852

30,403

28,998

28,918

28,896

28,828

28,812

27,286

1,688

1,688

1,688

1,688